Vimta Labs Limited has informed the Exchange about Transcript
VIMTALABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vimta Labs reported its highest-ever quarterly revenue of INR 993 million in Q1 FY26, up 31.4% year-on-year, driven by growth across pharmaceutical testing, food testing, and clinical research services. EBITDA rose 33.1% to INR 354 million with margins of 35.7%, while profit after tax grew 35.9% to INR 189 million. The company passed an unannounced US FDA GCP inspection with no Form 483 observations and received a cGMP compliance letter from ANSM EMA. The Board has approved a 1:1 bonus issue. Capex of around INR 100 crore is planned for FY26, with about 30% earmarked for a new biologics contract research and development facility targeted for commercialization in Q1 FY27. Management is targeting a quarterly revenue run-rate of INR 120-125 crore and indicated growth of 15-20% annually. The company remains net debt-free with cash of INR 379.3 million.
Strong quarterly performance with record revenue, healthy margins, and successful regulatory inspections reinforce growth visibility. However, management flagged a potential 1-2% EBITDA margin compression in coming quarters due to new facility maintenance costs. The 1:1 bonus issue rewards shareholders, while the biologics expansion adds a new long-term growth lever.